Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.99%
1,093.81
+10.77
+0.99%
—1,083.041,082.631,099.011,080.59——
SIXC
Communications
SIXC
Communications
SIXC
+1.06%
608.77
+6.39
+1.06%
—602.38602.38609.75599.75——
SIXE
Energy
SIXE
Energy
SIXE
+0.96%
1,254.81
+11.98
+0.96%
—1,242.831,229.311,258.881,220.51——
SIXI
Industrials
SIXI
Industrials
SIXI
+2.76%
1,761.11
+47.29
+2.76%
—1,713.821,715.471,763.111,715.47——
SIXM
Financials
SIXM
Financials
SIXM
+0.40%
642.58
+2.59
+0.40%
—639.99636.98644.04631.81——
SIXR
Staples
SIXR
Staples
SIXR
+1.63%
851.13
+13.67
+1.63%
—837.46840.30852.55840.30——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.76%
217.98
+3.76
+1.76%
—214.22214.22218.25214.05——
SIXT
Technology
SIXT
Technology
SIXT
+0.23%
3,211.83
+7.45
+0.23%
—3,204.383,215.043,217.443,159.90——
SIXU
Utilities
SIXU
Utilities
SIXU
+2.55%
948.98
+23.60
+2.55%
—925.38927.91949.76927.91——
SIXV
Health care
SIXV
Health care
SIXV
+2.20%
1,474.52
+31.81
+2.20%
—1,442.711,443.011,477.901,443.01——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+1.30%
2,392.12
+30.78
+1.30%
—2,361.342,391.002,399.182,354.52——
1BIIB:BIT
Biogen Inc
€164.36
-0.72%
(-1.20) 1D
Apr 30, 5:26:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 1BIIB...
Open
€164.58
High
€164.58
Low
€164.36
Mkt. cap
27.94B
Avg. vol.
29.00
Volume
62.00
52-wk high
€171.85
52-wk low
€103.00
No. of employees
8K
News stories
From sources across the web
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
2.65B
2.53B
2.28B
2.48B
Cost of goods sold
946.20M
508.60M
443.40M
-
Cost of revenue
946.20M
508.60M
443.40M
-
Research and development expenses
-
431.80M
501.00M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
581.30M
592.80M
685.20M
-
Operating expense
783.70M
1.25B
1.39B
-
Total operating expenses
1.73B
1.76B
1.83B
-
Operating income
915.60M
778.60M
447.70M
-
Other non operating income
-3.30M
15.80M
17.40M
-
EBT including unusual items
744.00M
557.30M
-56.00M
-
EBT excluding unusual items
861.60M
748.30M
423.10M
-
Income tax expense
109.20M
90.80M
-7.10M
-
Effective tax rate
14.68%
16.29%
12.68%
-
Other operating expenses
75.00M
87.20M
69.90M
-
Net income
634.80M
466.50M
-48.90M
-
Net profit margin
24.00%
18.40%
-2.15%
12.89%
Earnings per share
5.47
4.81
1.99
3.57
Interest and investment income
32.30M
31.60M
37.20M
-
Interest expense
-72.60M
-67.40M
-67.50M
-
Net interest expenses
-40.30M
-35.80M
-30.30M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
1.11B
980.80M
647.90M
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer